New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
14:43 EDTABMDAbiomed may have to obtain stringent approval for Impella, says Piper
Piper Jaffray predicts that Abiomed could be forced to obtain a PMA, or pre-market approval, for its Impella device. Pre-market approvals are the most stringent type of device marketing application required by the FDA, according to the agency's website. The firm thinks the company will have to conduct a series of new studies, but it maintains an Overweight rating on the stock, citing valuation. However, the firm expects the shares to remain range-bound in the near-term.
News For ABMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2016
07:07 EDTABMDAbiomed sees Q4 revenue $90M, consensus $85.11M
Subscribe for More Information
07:07 EDTABMDAbiomed raises FY16 revenue outlook to $326M from $305M-$315M
Subscribe for More Information
07:06 EDTABMDAbiomed reports Q3 EPS 23c, consensus 15c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use